Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.
- Resource Type
- Authors
- Salmon JM; Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC, 3002, Australia.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.; Bots M; Laboratory of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.; Vidacs E; Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC, 3002, Australia.; Stanley KL; Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC, 3002, Australia.; Atadja P; China Novartis Institutes for Biomedical Research, No. 2 BoYun Road, Pudong, Shanghai, 201203, China.; Zuber J; Research Institute of Molecular Pathology (IMP), Dr. Bohr-Gasse 7, A-1030, Vienna, Austria.; Johnstone RW; Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC, 3002, Australia. ricky.johnstone@petermac.org.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia. ricky.johnstone@petermac.org.
- Source
- Publisher: BiomedCentral Country of Publication: Germany NLM ID: 101516977 Publication Model: Electronic Cited Medium: Internet ISSN: 1868-7083 (Electronic) Linking ISSN: 18687075 NLM ISO Abbreviation: Clin Epigenetics Subsets: PubMed not MEDLINE; MEDLINE
- Subject
- Language
- English
An amendment to this paper has been published and can be accessed via the original article.